WallStSmart

AbbVie Inc (ABBV)vsConstellation Energy Corp (CEG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 146% more annual revenue ($62.82B vs $25.53B). CEG leads profitability with a 9.1% profit margin vs 5.8%. ABBV appears more attractively valued with a PEG of 0.57. ABBV earns a higher WallStSmart Score of 63/100 (C+).

ABBV

Buy

63

out of 100

Grade: C+

Growth: 4.0Profit: 8.0Value: 4.0Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

CEG

Hold

43

out of 100

Grade: D

Growth: 4.0Profit: 6.5Value: 2.7Quality: 6.0
Piotroski: 6/9Altman Z: 1.14
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-20.5%)

Margin of Safety

-20.5%

Fair Value

$168.19

Current Price

$201.55

$33.36 premium

UndervaluedFair: $168.19Overvalued
CEGSignificantly Overvalued (-44.5%)

Margin of Safety

-44.5%

Fair Value

$191.58

Current Price

$303.63

$112.05 premium

UndervaluedFair: $191.58Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.3/10
Market CapQuality
$358.55B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Debt/EquityHealth
-21.0610/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.578/10

Growing faster than its price suggests

Free Cash FlowQuality
$4.89B8/10

Generating 4.9B in free cash flow

CEG1 strengths · Avg: 9.0/10
Market CapQuality
$112.78B9/10

Large-cap with strong market position

Areas to Watch

ABBV4 concerns · Avg: 2.3/10
Profit MarginProfitability
5.8%3/10

5.8% margin — thin

P/E RatioValuation
98.9x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-45.8%2/10

Earnings declined 45.8%

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

CEG4 concerns · Avg: 2.0/10
PEG RatioValuation
3.742/10

Expensive relative to growth rate

P/E RatioValuation
42.0x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-48.9%2/10

Earnings declined 48.9%

Free Cash FlowQuality
$-181.00M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.

Bull Case : CEG

The strongest argument for CEG centers on Market Cap. Revenue growth of 12.9% demonstrates continued momentum.

Bear Case : ABBV

The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 98.9x leaves little room for execution misses.

Bear Case : CEG

The primary concerns for CEG are PEG Ratio, P/E Ratio, EPS Growth. A P/E of 42.0x leaves little room for execution misses.

Key Dynamics to Monitor

CEG carries more volatility with a beta of 1.16 — expect wider price swings.

CEG is growing revenue faster at 12.9% — sustainability is the question.

ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ABBV scores higher overall (63/100 vs 43/100) and 12.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Constellation Energy Corp

UTILITIES · UTILITIES - INDEPENDENT POWER PRODUCERS · USA

Constellation Energy Corporation is an energy producer in the United States. The company is headquartered in Baltimore, Maryland.

Visit Website →

Want to dig deeper into these stocks?